# EDGAR Filing Document

**Accession Number:** 0002101167
**File Stem:** 0002101167-26-000002
**Filing Date:** 2026-1
**Character Count:** 5480
**Document Hash:** 1d5cd3446ce2eb9828872a3dcc19aa18
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0002101167-26-000002.hdr.sgml**: 20260126

**ACCESSION NUMBER**: 0002101167-26-000002

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251125

**FILED AS OF DATE**: 20260126

**DATE AS OF CHANGE**: 20260126

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** BKB Growth Investments, LLC
- **CENTRAL INDEX KEY:** 0002101167

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38529
- **FILM NUMBER:** 26560770

**BUSINESS ADDRESS:**
- **STREET 1:** 200 GARRETT STREET, SUITE S
- **CITY:** CHARLOTTESVILLE
- **STATE:** VA
- **ZIP:** 22902
- **BUSINESS PHONE:** 434-980-8100

**MAIL ADDRESS:**
- **STREET 1:** 200 GARRETT STREET, SUITE S
- **CITY:** CHARLOTTESVILLE
- **STATE:** VA
- **ZIP:** 22902
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Verrica Pharmaceuticals Inc.
- **CENTRAL INDEX KEY:** 0001660334
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 463137900
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 10 NORTH HIGH STREET
- **STREET 2:** SUITE 200
- **CITY:** WEST CHESTER
- **STATE:** PA
- **ZIP:** 19380
- **BUSINESS PHONE:** 484-453-3300

**MAIL ADDRESS:**
- **STREET 1:** 10 NORTH HIGH STREET
- **STREET 2:** SUITE 200
- **CITY:** WEST CHESTER
- **STATE:** PA
- **ZIP:** 19380

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>BKB Growth Investments, LLC<br><sub>(Last) (First) (Middle)</sub><br>C/O TIGER LILY CAPITAL, LLC<br>200 GARRETT STREET, SUITE S<br><sub>(Street)</sub><br>CHARLOTTESVILLE, VA 22902<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Verrica Pharmaceuticals Inc. [ VRCA ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2025-11-25 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [X] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 3348372 | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Series B Warrants (right to buy) | <sup>(1)(2)</sup> | 2029-11-22 | Common Stock | 224719 | $1.335 | D |  |
| Series C Warrants (right to buy) | <sup>(1)(3)</sup> | 2030-11-25 | Common Stock | 687690 | $6.315 | D |  |

---

### Footnotes:

(1) Immediately exercisable.

(2) The Reporting Person will not be entitled to exercise any portion of a Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 19.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise.

(3) The Reporting Person will not be entitled to exercise any portion of a Series C Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 19.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise.

**Signature:** BKB Growth Investments, LLC, By: Tiger Lily Capital, LLC, its manager By: /s/ Paul Manning, its manager  
**Date:** 2026-01-26

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**